As the FDA unveils a parade of initiatives aimed at accelerating drug development for rare diseases, experts appeal for a ...
Former Novo Nordisk CSO Marcus Schindler on R&D leadership, pharma innovation, scientific discovery, AI, global talent, DEI, biotech, drug development strategy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback